Torsdag 21 November | 22:42:29 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-10-22 - Kvartalsrapport 2025-Q3
2025-07-18 - Kvartalsrapport 2025-Q2
2025-04-29 - Kvartalsrapport 2025-Q1
2025-04-29 - Årsstämma
2025-02-13 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2023-06-02 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-03-24 - Extra Bolagsstämma 2023
2023-03-08 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-10-03 - Extra Bolagsstämma 2022
2022-08-24 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-03-09 - Bokslutskommuniké 2021
2021-11-26 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksamma inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.
2024-08-15 07:45:00

Strong organic growth and margin expansion

  • Net revenue increased by 12 per cent to EUR 91.0m (81.3) with organic growth of 11 per cent
  • Adjusted EBITA increased 22 per cent to EUR 24.7m (20.3) corresponding to a margin of 27.2 per cent (25.0)
  • Operating profit (EBIT) increased 30 per cent to EUR 13.2m (10.1)
  • Profit of EUR 5.1m (3.2) and earnings per share before and after dilution EUR 0.01 (0.01)
  • Cash flow from operating activities of EUR 5.9m (-58.5)

“We report double digit organic growth, grew adjusted EBITA with 22 per cent and improved our margins in the second quarter. Our three largest segments delivered strong performance, and we continued to execute on our strategic agenda, addressing unmet medical needs of companion animals across the globe by delivering innovation, driving cross-sales and operational improvements as well as expanding our educations”, says Patrik Eriksson, CEO of Vimian Group and continues:

“I see significant runway for both organic and acquisition driven growth over the years to come. We are well-capitalised and focused on broadening the portfolio and strengthening our geographic reach.”

A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://conference.financialhearings.com/teleconference/?id=50047233

To attend the webcast:
Link: https://ir.financialhearings.com/vimian-group-q2-report-2024

Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.